Under a tenth of individuals that would benefit from weight-loss injections like Wegovy have access to them, caution the global health agency as it issues its first guidance on the drugs.
Given over a billion individuals worldwide now obese, it is urging increased and just availability to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"Our latest guidance affirms that excess weight is a chronic disease that can be addressed with holistic and ongoing support," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are significant barriers to universal access to the injections that can assist patients in reducing significant weight, says the body.
Skinny Jab Scarcity
Even in the present best projected outlook, the production of GLP-1 therapies would only suffice for approximately 100 million people – fewer than 10% of the global need, per the WHO.
The advice encourages countries and companies to expand availability, by approaches like voluntary licensing.
A patent on the active ingredient – the main component of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Weight-Loss Jabs Function
GLP-1 drugs imitate a natural hormone to slow digestion, reduce hunger and increase satiety so people eat less.
Patients typically start to lose weight after several weeks of starting on the once-weekly jabs.
Studies suggests people may see weight return a year later of halting the drug, as their typical food cravings come back.
Being carrying excess weight elevates your likelihood for experiencing diseases, such as diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight impacts individuals in all nations and was associated with millions of fatalities worldwide in 2024, as per the health agency.
